Quarterly ResultMay 14, 2026, 04:47 PM
Calidi Biotherapeutics Q1 Net Loss $4.11M; EPS $(0.43)
AI Summary
Calidi Biotherapeutics reported a net loss of $4.11 million for Q1 2026, an improvement from $5.06 million in Q1 2025, with diluted EPS of $(0.43). Despite this, the company disclosed substantial doubt about its ability to continue as a going concern within the next 12 months due to recurring losses and negative cash flows. General and administrative expenses decreased significantly, while research and development expenses slightly increased.
Key Highlights
- Substantial doubt about ability to continue as a going concern within 12 months.
- Net loss for Q1 2026 was $4.11 million, compared to $5.06 million in Q1 2025.
- Net loss per share was $(0.43) for Q1 2026, compared to $(2.21) in Q1 2025.
- Cash and restricted cash totaled $6.85 million at March 31, 2026.
- Cash used in operating activities decreased to $4.12 million from $7.13 million year-over-year.
- General and administrative expenses decreased to $1.60 million from $2.64 million year-over-year.
- Research and development expenses increased to $2.59 million from $2.43 million year-over-year.
- Total equity increased to $4.94 million at March 31, 2026, from $3.76 million at December 31, 2025.
Price Impact
More from CLDI